Ole Hudowenz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ole Hudowenz has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Philipp Klemm
Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Bad Nauheim, Germany
4 shared publications Martin Nitschke
Department of Internal Medicine I, Division of Nephrology, University Medical Center Schleswig-Holstein – Campus Lübeck, Lübeck
3 shared publications- Uwe Lange
Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Bad Nauheim, Germany
3 shared publications - Franz Wegner
Fraunhofer Research Institution for Individualized Medical Technology and Engineering IMTE Lübeck Germany
2 shared publications - Gabriel Dischereit
Department of Rheumatology, Immunology, Osteology and Physical Medicine, Campus Kerckhoff of Justus Liebig University Gießen, Bad Nauheim, Germany
2 shared publications Niklas Gebauer
Department of Hematology and Oncology, University Medical Center Schleswig-Holstein – Campus Lübeck, Lübeck
2 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Idiopathic multicentric Castleman - TAFRO syndrome can mimic sepsis and myeloid neoplasia
- 30 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessIdiopathic multicentric Castleman - TAFRO syndrome can mimic sepsis and myeloid neoplasia
- 31 October 2025
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 122 (22) , 610
Acute anuric kidney injury due to subtotal renal artery occlusion
- 31 October 2025
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 122 (22) , 610
Acute anuric kidney injury due to subtotal renal artery occlusion
- 5 March 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (5) , 1517-1518
Radiopaque intestinal contents due to simultaneous ingestion of lanthanum carbonate and sodium zirconium cyclosilicate: a nephrology image
- 5 March 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (5) , 1517-1518
Radiopaque intestinal contents due to simultaneous ingestion of lanthanum carbonate and sodium zirconium cyclosilicate: a nephrology image
- 20 November 2024
- Published by Elsevier in Kidney International
- Vol. 106 (6) , 1189
Intravascular large B-cell-lymphoma: a rare post-transplant lymphoproliferative disease
- 20 November 2024
- Published by Elsevier in Kidney International
- Vol. 106 (6) , 1189
Intravascular large B-cell-lymphoma: a rare post-transplant lymphoproliferative disease
- 26 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (10) , e15463
Successful Kidney Transplantation Despite Therapeutic Anticoagulation—Effective Apixaban Elimination by Hemoadsorption
- 26 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (10) , e15463
Successful Kidney Transplantation Despite Therapeutic Anticoagulation—Effective Apixaban Elimination by Hemoadsorption
- 25 August 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (2) , e71-e72
Eosinophilic fasciitis in eosinophilic granulomatosis with polyangiitis
Ole Hudowenz, Sabrina Arnold, Inge Derad, Peter Lamprecht; Eosinophilic fasciitis in eosinophilic granulomatosis with polyangiitis, Rheumatology, , kead419, htt
- 25 August 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (2) , e71-e72
Eosinophilic fasciitis in eosinophilic granulomatosis with polyangiitis
Ole Hudowenz, Sabrina Arnold, Inge Derad, Peter Lamprecht; Eosinophilic fasciitis in eosinophilic granulomatosis with polyangiitis, Rheumatology, , kead419, htt
- Open Access
- 21 March 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (6) , 1073
Clinical Images: Optic perineuritis in relapsing granulomatosis with polyangiitis
- 21 March 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (6) , 1073
Open AccessClinical Images: Optic perineuritis in relapsing granulomatosis with polyangiitis
- 4 May 2022
- Published by Taylor & Francis in European Journal of Physiotherapy
- Vol. 24 (3) , 158-163
Multimodal physical therapy for treating primary and secondary fibromyalgia - German multimodal rheumatologic complex treatment
Objectives: Multimodal rheumatologic complex therapy (MRCT) delivers various modalities of physical therapy (PT) to patients with rheumatic diseases. We conducted a monocentric retrospective analysis of the effects of MRCT on pain and disease activity in patients with primary (PFM) and secondary fibromyalgia (SFM). Methods: 102 treatment episodes (N) applied to 83 patients (n) with PFM (N = 50;n = 39) and SFM (N = 52,n = 44) were analysed. Of the latter, 23 had rheumatoid arthritis (RA) and 21 spondyloarthritis (SpA). We evaluated changes in pain intensity, functional status and disease activity before and after a MRCT episode. In addition, we assessed influences of various patient characteristics and analysed treatment responses in PFM and SFM. Results: MRCT resulted in significant reduction of pain (NRS,p < 0.0001) and disease activity (FIQ,p = 0.001). In SFM, disease activity of the underlying disease (i.e. RA or SpA) was significantly reduced. Various aspects of the disease did not have a significant effect on the outcome parameters. Treatment effects were not significantly different in PFM and SFM. Conclusion: MRCT significantly decreases pain and disease activity in patients with FM, irrespective of the course of disease, and is equally effective in both PFM and SFM, thus underlining the importance of PT in the treatment of FM.
- 4 May 2022
- Published by Taylor & Francis in European Journal of Physiotherapy
- Vol. 24 (3) , 158-163
Multimodal physical therapy for treating primary and secondary fibromyalgia - German multimodal rheumatologic complex treatment
Objectives: Multimodal rheumatologic complex therapy (MRCT) delivers various modalities of physical therapy (PT) to patients with rheumatic diseases. We conducted a monocentric retrospective analysis of the effects of MRCT on pain and disease activity in patients with primary (PFM) and secondary fibromyalgia (SFM). Methods: 102 treatment episodes (N) applied to 83 patients (n) with PFM (N = 50;n = 39) and SFM (N = 52,n = 44) were analysed. Of the latter, 23 had rheumatoid arthritis (RA) and 21 spondyloarthritis (SpA). We evaluated changes in pain intensity, functional status and disease activity before and after a MRCT episode. In addition, we assessed influences of various patient characteristics and analysed treatment responses in PFM and SFM. Results: MRCT resulted in significant reduction of pain (NRS,p < 0.0001) and disease activity (FIQ,p = 0.001). In SFM, disease activity of the underlying disease (i.e. RA or SpA) was significantly reduced. Various aspects of the disease did not have a significant effect on the outcome parameters. Treatment effects were not significantly different in PFM and SFM. Conclusion: MRCT significantly decreases pain and disease activity in patients with FM, irrespective of the course of disease, and is equally effective in both PFM and SFM, thus underlining the importance of PT in the treatment of FM.
- 11 August 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 22 (12) , E166
Anti-HMGCR myopathy with cardiac involvement
- 11 August 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 22 (12) , E166
Anti-HMGCR myopathy with cardiac involvement
- Open Access
- 21 October 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (6) , 1-6
Case report of severe PCR-confirmed COVID-19 myocarditis in a European patient manifesting in mid January 2020
Background: Viral genesis is the most common cause of myocarditis. COVID-19-associated myocarditis seems to be a notable extrapulmonary manifestation, which may result in the need for a different treatment. There has been no positive polymerase chain reaction (PCR) testing of SARS-CoV-2 in heart specimens, thus far. Case summary: A 48-year-old male patient presented with fever, dyspnoea, and haemoptysis. Laboratory findings showed highly elevated inflammatory and cardiac damage markers. Thoracic computed tomography (CT) revealed bilateral, patchy peripheral ground-glass opacities with a crazy-paving pattern, focal consolidations, and mild pleural effusions. Cardiac imaging with echocardiography and magnetic resonance imaging (MRI) detected a reduced biventricular function. MRI additionally showed myocardial oedema and late gadolinium enhancement. Lung and heart biopsies were performed, revealing alveolitis with necrosis and acute lymphocytic myocarditis. Testing for usual cardiotropic viruses was negative, and no aspects of vasculitis or granuloma could be found. Due to fulfilling the criteria, the patient was diagnosed with rheumatic vasculitis. Treatment with cyclophosphamide and steroids was initiated. Later, the patient reported a history of travel to Tyrol in mid January. Consequently, PCR testing for SARS-CoV-2 was performed, which was positive in the heart specimen. Immunosuppressive treatment was discontinued. During a follow-up visit at the end of April, the patient’s recovery was stable. Discussion: In COVID-19 infections, myocardial inflammation can be present as an extrapulmonary manifestation. Positive PCR testing confirms myocardial invasion of the virus. Imaging and laboratory studies correlate with the histopathological findings, and thus should be performed in COVID-19 patients who are suspicious for myocarditis. Supportive treatment with steroids may be useful in these patients.
- 21 October 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 4 (6) , 1-6
Open AccessCase report of severe PCR-confirmed COVID-19 myocarditis in a European patient manifesting in mid January 2020
Background: Viral genesis is the most common cause of myocarditis. COVID-19-associated myocarditis seems to be a notable extrapulmonary manifestation, which may result in the need for a different treatment. There has been no positive polymerase chain reaction (PCR) testing of SARS-CoV-2 in heart specimens, thus far. Case summary: A 48-year-old male patient presented with fever, dyspnoea, and haemoptysis. Laboratory findings showed highly elevated inflammatory and cardiac damage markers. Thoracic computed tomography (CT) revealed bilateral, patchy peripheral ground-glass opacities with a crazy-paving pattern, focal consolidations, and mild pleural effusions. Cardiac imaging with echocardiography and magnetic resonance imaging (MRI) detected a reduced biventricular function. MRI additionally showed myocardial oedema and late gadolinium enhancement. Lung and heart biopsies were performed, revealing alveolitis with necrosis and acute lymphocytic myocarditis. Testing for usual cardiotropic viruses was negative, and no aspects of vasculitis or granuloma could be found. Due to fulfilling the criteria, the patient was diagnosed with rheumatic vasculitis. Treatment with cyclophosphamide and steroids was initiated. Later, the patient reported a history of travel to Tyrol in mid January. Consequently, PCR testing for SARS-CoV-2 was performed, which was positive in the heart specimen. Immunosuppressive treatment was discontinued. During a follow-up visit at the end of April, the patient’s recovery was stable. Discussion: In COVID-19 infections, myocardial inflammation can be present as an extrapulmonary manifestation. Positive PCR testing confirms myocardial invasion of the virus. Imaging and laboratory studies correlate with the histopathological findings, and thus should be performed in COVID-19 patients who are suspicious for myocarditis. Supportive treatment with steroids may be useful in these patients.